Dianthus Therapeutics (DNTH) has been on investors’ radar after recent share price swings, with the stock last closing at ...

This biotech developing therapies for rare autoimmune diseases reported notable insider selling in its most recent SEC ...

Dianthus Therapeutics (NASDAQ:DNTH) announced a licensing deal worth up to $1B with Nanjing Leads Biolabs on Thursday to obtain exclusive rights to an autoimmune disease therapy developed by the ...

A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website. About Dianthus Therapeutics Dianthus Therapeutics, Inc. is a ...

Dianthus Therapeutics is on a mission to reduce the number of injections autoimmune disease patients have to receive, using $100 million in series A financing to send its antibody candidate into the ...

Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase ...

Dianthus Therapeutics (NASDAQ:DNTH) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of ...

Jane explores the diversity of dianthus. Dianthus are a favourite for cottage gardens. They're often called carnations, clove pinks or just pinks, because they look like someone's used pinking shears ...